Description
Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge.More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.- Discusses the development and application of virus-based therapy against cancer- Covers the safety and potential drawbacks or side-effects of the use of apathogenic viruses as therapeutic agents- Explores the use of viruses to treat future (newly emerging) viruses
Table of Contents
1. Rethinking viruses: Beyond the pathogen paradigm in virome-host interactions2. Three out of four new diseases are zoonotic: Neglected pandemic threats in the United States3. Exploiting viral interference for therapy4. Fighting fire with fire: Using non-pathogenic rhinoviruses and attenuated oral polioviruses to combat unrelated viral infections5. Beneficial non-specific effects of live vaccines against unrelated infections6. A post-infection Plan B to complement vaccination against RNA viruses7. Impact of GB Virus C Viraemia on the clinical outcome in HIV-1-Infected patients8. Conventional Acyclovir complemented with immunostimulatory IBDV may reduce the crusting time of shingles to one-third9. Combination of IBDV with low doses of Nivolumab Plus Ipilimumab could provide functional cure in chronic hepatitis b virus infections10. Breakthrough infection can be achieved in the presence of neutralizing antibodies by multiple administrations of viruses11. Reverse genetics improves safety of IBDV (R903/78) therapeutic vaccine candidate12. Infectious Bursal Disease Virus (IBDV) is simple to manufacture and is affordable13. Counteracting immunosuppression in the tumor microenvironment by immunostimulatory viruses and ICIs
